1. Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.223
Figure 1 Reversal agents for non-vitamin K antagonist oral anticoagulants
Figure 1 | Reversal agents for non-vitamin K antagonist oral anticoagulants. a | Idarucizumab is an antibody antigen-binding fragment (Fab) that binds to dabigatran with an affinity >350 times that of thrombin and effectively and immediately reverses its anticoagulant effect. b | Andexanet alfa is a modified recombinant coagulation factor Xa molecule that competitively binds factor Xa inhibitors (apixaban, betrixaban, edoxaban, and rivaroxaban) and is catalytically inactive. Andexanet has been modified to include amino acid substitutions and deletion of the γ-carboxyglutamic acid (Gla)-rich membrane-binding domain to prevent assembly of factor Xa and factor Va and creation of the prothrombinase complex. c | Ciraparantag is a synthetic inorganic molecule that binds multiple anticoagulation agents through noncovalent hydrogen bonding and charge–charge interactions. LMWH, low-molecular-weight heparin; UFH, unfractionated heparin.
Levy, J. H. et al. (2018) Reversal agents for non-vitamin K antagonist oral anticoagulants
Nat. Rev. Cardiol. doi: /nrcardio